The Effect of SLC2A3 Expression on Cisplatin Resistance of Colorectal Cancer Cells

Li, Yan; Lei, Hailong; Zhang, Ming; Wu, Guangming; Guo, Caiyun; Yang, Zhen; Zhang, Jingting; Wang, Yuan; Zhu, Jianbin; Du, Yongzhe

doi:10.18502/ijph.v50i12.7941

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 SLC2A3 exerts multiple biological functions in different cancers, including tumor EMT, ferroptosis, glycolytic reprogramming, drug resistance and immunity. [55][56][57][58][59] Immune cell infiltration analysis showed that SLC11A1 and SLC2A3 expression was positively correlated with the infiltration levels of neutrophils, macrophages, dendritic cells, CD4+ T cells and CD8+ T cells. Moreover, the higher the expression levels of SLC11A1 and SLC2A3, the lower the tumor purity.…”

Section: Discussionmentioning

confidence: 99%

“…Reportedly, SLC11A1 not only predicts the prognosis of colorectal cancer and hepatocellular carcinoma 52,53 but also serves as a stratification indicator for immunotherapy or chemotherapy in glioma patients 54 . SLC2A3 exerts multiple biological functions in different cancers, including tumor EMT, ferroptosis, glycolytic reprogramming, drug resistance and immunity 55–59 . Immune cell infiltration analysis showed that SLC11A1 and SLC2A3 expression was positively correlated with the infiltration levels of neutrophils, macrophages, dendritic cells, CD4+ T cells and CD8+ T cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Constructing and validating a risk model based on neutrophil‐related genes for evaluating prognosis and guiding immunotherapy in colon cancer

Wang,

Qiu

et al. 2024

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundColon cancer is one of the most common digestive tract malignancies. Although immunotherapy has brought new hope to colon cancer patients, there is still a large proportion of patients who do not benefit from immunotherapy. Studies have shown that neutrophils can interact with immune cells and immune factors to affect the prognosis of patients.MethodsWe first determined the infiltration level of neutrophils in tumors using the CIBERSORT algorithm and identified key genes in the final risk model by Spearman correlation analysis and subsequent Cox analysis. The risk score of each patient was obtained by multiplying the Cox regression coefficient and the gene expression level, and patients were divided into two groups based on the median of risk score. Differences in overall survival (OS) and progression‐free survival (PFS) were assessed by Kaplan–Meier survival analysis, and model accuracy was validated in independent dataset. Differences in immune infiltration and immunotherapy were evaluated by immunoassay. Finally, immunohistochemistry and western blotting were performed to verify the expression of the three genes in the colon normal and tumor tissues.ResultsWe established and validated a risk scoring model based on neutrophil‐related genes in two independent datasets, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, with SLC11A1 and SLC2A3 as risk factors and MMP3 as a protective factor. A new nomogram was constructed and validated by combining clinical characteristics and the risk score model to better predict patients OS and PFS. Immune analysis showed that patients in the high‐risk group had immune cell infiltration level, immune checkpoint level and tumor mutational burden, and were more likely to benefit from immunotherapy.ConclusionsThe low‐risk group showed better OS and PFS than the high‐risk group in the neutrophil‐related gene‐based risk model. Patients in the high‐risk group presented higher immune infiltration levels and tumor mutational burden and thus may be more responsive to immunotherapy.

show abstract